<PAGE>
<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
- --- SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1994
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
- --- SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______________ to _______________
Commission file number 1-5851
Rhone-Poulenc Rorer Inc.
- -----------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Commonwealth of Pennsylvania 23-1699163
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
500 Arcola Road
Collegeville, Pennsylvania 19426-0107
- -----------------------------------------------------------------
(Address of principal (Zip Code)
executive offices)
(215) 454-8000
- -----------------------------------------------------------------
(Registrant's telephone number, including area code)
(Former name, address and fiscal year,
if changed since last report.)
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15 (d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes x No
--- ---
Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date.
135,659,937 shares as of April 22, 1994.
The exhibit index is located on page 21.
<PAGE>
<PAGE> 2
RHONE-POULENC RORER INC.
TABLE OF CONTENTS
-----------------
Page
PART I. FINANCIAL INFORMATION
Item 1. Financial statements:
Report of Independent Accountants 3
Condensed Consolidated Statements of Income 4
Condensed Consolidated Balance Sheets 5
Condensed Consolidated Statements of Cash Flows 6
Notes to Condensed Consolidated Financial Statements 7
Item 2. Management's Discussion and Analysis of Results of
Operations and Financial Condition 11
PART II. OTHER INFORMATION
Item 1. Legal Proceedings 15
Item 5. Submission of Matters to a
Vote of Security Holders 19
Item 6. Exhibits and Reports on Form 8-K 19
- 2 -
<PAGE>
<PAGE> 3
REPORT OF INDEPENDENT ACCOUNTANTS
To the Shareholders of Rhone-Poulenc Rorer Inc.:
We have reviewed the accompanying condensed consolidated balance
sheet of Rhone-Poulenc Rorer Inc. and subsidiaries as of
March 31, 1994, and the related condensed consolidated statements
of income and cash flows for the three-month periods ended March
31, 1994 and 1993. These financial statements are the
responsibility of the Company's management.
We conducted our review in accordance with standards established by
the American Institute of Certified Public Accountants. A review
of interim financial information consists principally of applying
analytical procedures to financial data and making inquiries of
persons responsible for financial and accounting matters. It is
substantially less in scope than an audit in accordance with
generally accepted auditing standards, the objective of which is
the expression of an opinion regarding the financial statements
taken as a whole. Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications
that should be made to the condensed consolidated financial
statements referred to above for them to be in conformity with
generally accepted accounting principles.
We have previously audited, in accordance with generally accepted
auditing standards, the consolidated balance sheet of Rhone-Poulenc
Rorer Inc. and subsidiaries as of December 31, 1993, and the
related consolidated statements of income and cash flows for the
year then ended (not presented herein) and, in our report, which
includes an explanatory paragraph on the Company's change in its
method of accounting for income taxes in 1992, dated January 26,
1994, we expressed an unqualified opinion on those consolidated
financial statements. In our opinion, the information set forth in
the accompanying condensed consolidated balance sheet as of
December 31, 1993, is fairly stated, in all material respects, in
relation to the consolidated balance sheet from which it has been
derived.
/s/ COOPERS & LYBRAND
-----------------------------
COOPERS & LYBRAND
Philadelphia, Pennsylvania
April 22, 1994
- 3 -
<PAGE>
<PAGE> 4
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements
- -------------------------------
RHONE-POULENC RORER INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited - amounts in millions except per share data)
<TABLE>
<CAPTION>
Three Months Ended
March 31
-----------------------
1994 1993
---------- ----------
<S> <C> <C>
Net sales $870.6 $916.3
Cost of products sold 293.3 308.8
Selling, delivery and administrative expenses 318.4 326.5
Research and development expense 129.1 127.8
---------- ----------
Operating income 129.8 153.2
Interest expense - net 11.8 20.5
Other (income) expense - net 8.1 (3.4)
---------- ----------
Income before income taxes 109.9 136.1
Provision for income taxes 32.0 39.7
---------- ----------
Net income 77.9 96.4
Dividend on preferred stock (4.2) (2.2)
---------- ----------
Net income available to common shareholders $ 73.7 $ 94.2
========== ==========
Earnings per common share $ .54 $ .68
========== ==========
Cash dividend per common share $ .28 $ .22
Average common shares outstanding 136.5 138.3
<FN>
See accompanying Notes to Condensed Consolidated Financial Statements.
</FN>
</TABLE>
- 4 -
<PAGE>
<PAGE> 5
RHONE-POULENC RORER INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited - dollars in millions)
<TABLE>
<CAPTION>
March 31, December 31,
1994 1993
------------ --------------
<S> <C> <C>
ASSET
Current:
Cash and cash equivalents $ 37.0 $ 35.4
Short-term investments 7.1 --
Trade accounts and notes receivable, less
reserves of $50.7 (1993: $68.3) 604.7 746.6
Inventories 561.3 504.1
Other current assets 404.6 382.7
------------ -----------
Total current assets 1,614.7 1,668.8
Time deposits, at cost 56.6 64.3
Property, plant and equipment,
net of accumulated depreciation
$967.5 (1993: $926.6) 1,042.2 1,032.0
Goodwill, net of accumulated amortization
of $182.8 (1993: $172.1) 688.4 676.5
Intangibles, net of accumulated amortization
of $101.0 (1993: $96.5) 212.2 206.1
Other assets 406.6 402.5
------------- -----------
Total assets $4,020.7 $4,050.2
============= ===========
LIABILITIES
Current:
Short-term debt $ 92.4 $ 108.6
Notes payable to Rhone-Poulenc S.A.
and affiliates 144.8 201.3
Accounts payable 335.2 365.6
Other current liabilities 496.0 546.7
------------ -----------
Total current liabilities 1,068.4 1,222.2
Long-term debt 527.0 432.2
Deferred income taxes 28.7 29.5
Other liabilities 552.7 545.1
------------ -----------
Total liabilities 2,176.8 2,229.0
Contingencies
SHAREHOLDERS' EQUITY
Market Auction Preferred Shares, without
par value (liquidation preference $1,000
per share); authorized, issued and
outstanding 225,000 shares 225.0 225.0
Money market preferred stock, without par
value (liquidation preference $100,000
per share); authorized, issued and
outstanding 1,750 shares 175.0 175.0
Common stock, without par value; stated
value $1 per share; authorized 200,000,000
shares; issued and outstanding 135,849,038
shares (1993: 136,996,345 shares) 139.0 139.0
Capital in excess of stated value 293.9 290.0
Retained earnings 1,242.7 1,207.3
Employee Benefits Trust (115.5) (75.8)
Cumulative translation adjustments (116.2) (139.3)
------------ -----------
Total shareholders' equity 1,843.9 1,821.2
------------ -----------
Total liabilities and shareholders' equity $4,020.7 $4,050.2
============ ===========
<FN>
See accompanying Notes to Condensed Consolidated Financial Statements.
</FN>
</TABLE>
- 5 -
<PAGE>
<PAGE> 6
RHONE-POULENC RORER INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited - dollars in millions)
<TABLE>
<CAPTION>
Three Months Ended
March 31,
----------------------
1994 1993
---------- ---------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided by operating activities $126.4 $160.9
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures (44.1) (54.0)
Investments acquired (sold), net (3.2) 6.6
Other investing activities, net (10.4) .2
---------- ---------
Net cash used in investing activities (57.7) (47.2)
CASH FLOWS FROM FINANCING ACTIVITIES:
Debt borrowings (repayments):
Long-term debt, net (14.1) 89.2
Short-term debt, net 24.9 (168.0)
Issuances of common stock 3.4 2.5
Shares repurchased for Employee Benefits
Trust (39.7) (4.6)
Dividends paid (42.2) (32.9)
---------- ---------
Net cash used in financing activities (67.7) (113.8)
Effect of exchange rate changes on cash .6 (1.0)
---------- ---------
Net increase (decrease) in cash and cash equivalents 1.6 (1.1)
Cash and cash equivalents at beginning of year 35.4 39.5
---------- ---------
Cash and cash equivalents at March 31 $ 37.0 $ 38.4
========== =========
<FN>
See accompanying Notes to Condensed Consolidated Financial Statements.
</FN>
</TABLE>
- 6 -
<PAGE>
<PAGE> 7
RHONE-POULENC RORER
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1. - RESULTS FOR INTERIM PERIODS
In the opinion of management, the accompanying unaudited condensed
consolidated financial statements reflect all adjustments necessary for a
fair presentation of financial position, cash flows and results of
operations for the periods presented.
Certain prior year items have been reclassified to conform to current
classifications.
The statements are presented in accordance with the requirements of Form
10-Q and do not include all disclosures required by generally accepted
accounting principles or those made in the Annual Report on Form 10-K. The
Annual Report on Form 10-K for the year 1993 is on file with the Securities
and Exchange Commission and should be read in conjunction with these
condensed consolidated financial statements.
NOTE 2. - INCOME TAXES
The Company records income tax expense based on an estimated full year
effective income tax rate. The first quarter estimated effective tax rate
was 29.1% and 29.2% in 1994 and 1993, respectively.
NOTE 3. - INVENTORIES
Inventories consisted of the following:
(Dollars in millions) March 31, 1994 December 31, 1993
----------------- -----------------
Finished goods $282.9 $235.3
Work in process 123.4 111.5
Raw materials and supplies 155.0 157.3
----------------- -----------------
$561.3 $504.1
================= =================
- 7 -
<PAGE>
<PAGE> 8
NOTE 4. - SHAREHOLDERS' EQUITY
<TABLE>
<CAPTION>
Market Money Common Capital
Auction market shares at in excess Employee Cumulative
Preferred preferred stated of stated Retained Benefits translation
Shares stock value value earnings Trust adjustments
--------- --------- --------- --------- --------- --------- -----------
(Dollars in millions)
<S> <C> <C> <C> <C> <C> <C> <C>
Balance, December 31, 1993 $225.0 $175.0 $139.0 $290.0 $1,207.3 $ (75.8) $ (139.3)
Net income 77.9
Cash dividend, $.28 per
common share (38.3)
Dividend on preferred stock (4.2)
Issuance of shares under
employee benefit plans 3.9
Repurchase of shares for
Employee Benefits Trust (39.7)
Translation adjustments 23.1
-------- ------- --------- --------- ---------- --------- ------------
Balance, March 31, 1994 $225.0 $175.0 $139.0 $293.9 $1,242.7 $ (115.5) $ (116.2)
======== ======= ========= ========= ========== ========= ============
<FN>
In March 1993, the Company's Board of Directors approved the repurchase of up to 5 million of its common shares on the open
market from time to time. During the first quarter of 1994, the Company repurchased approximately 1.1 million of its common
shares at a cost approximating $39.7 million. As of April 22, 1994, just over 3.3 million shares ($123.3 million) have been
acquired since the inception of the program. These shares are held in an Employee Benefits Trust to fund employee benefits in
the U.S.
</FN>
</TABLE>
- 8 -
<PAGE>
<PAGE> 9
NOTE 5. - RELATED PARTY TRANSACTIONS
Receivables from Rhone-Poulenc SA and affiliates (RP) at March 31, 1994
include $13.1 million in accounts receivable from sales of products and
services to RP and $27.8 million classified as other current assets.
Accounts payable related to the purchase of materials and services from RP
were $9.9 million at March 31, 1994; accrued and other liabilities due to
RP totaled $12.1 million.
As of March 31, 1994, the Company had $144.8 million short-term and $29.7
million long-term debt outstanding with RP.
Sales to RP in 1994 were $11.1 million in the first quarter; services
purchased from and interest paid to RP were $9.0 million. For the
comparable 1993 quarter, sales to RP were $11.1 million and amounts paid
to RP for services and interest were $12.0 million.
NOTE 6. - CONTINGENCIES
The Company is involved in litigation incidental to its business,
including, but not limited to: (1) approximately 258 pending lawsuits in
the United States, Canada and Ireland against the Company and its Armour
Pharmaceutical Company subsidiary ("Armour"), in which it is claimed by
individuals infected with the Human Immunodeficiency Virus (HIV) that their
infection with HIV and, in some cases, resulting illnesses, including
Acquired Immune Deficiency Syndrome-related conditions or death therefrom,
may have been caused by administration of antihemophilic factor (AHF)
concentrates processed by Armour in the early and mid-1980's. Armour has
also been named as a defendant in four proposed class action lawsuits filed
on behalf of HIV-infected hemophiliacs and their families. None of the
cases involves Armour's currently distributed AHF concentrates; (2) legal
actions pending against one or more subsidiaries of the Company and various
groupings of more than one hundred pharmaceutical companies, in which it
is generally alleged that certain individuals were injured as a result of
the development of various reproductive tract abnormalities because of in
utero exposure to diethylstilbestrol (DES) (typically, two former operating
subsidiaries of the Company are named as defendants, along with numerous
other DES manufacturers, when the claimant is unable to identify the
manufacturer); (3) antitrust actions alleging that the Company engaged in
price discrimination practices to the detriment of certain independent
community pharmacists; (4) an alleged infringement by the Company of a
process patent for the manufacture of bulk diltiazem, an ingredient in the
Company's product Dilacor XRR; these proceedings have been indefinitely
suspended; (5) potential responsibility relating to past waste disposal
practices, including potential involvement, for which the Company believes
its share of liability, if any, to be negligible, at two sites on the U.S.
National Priority List created by Superfund legislation.
The eventual outcomes of the above matters of pending litigation cannot be
predicted with certainty. The defense of these matters and the defense of
expected additional lawsuits related to these matters may require
substantial legal defense expenditures. The Company follows Statement of
Financial Accounting Standards No. 5 in determining whether to recognize
losses and accrue liabilities relating to such matters. Accordingly, the
Company recognizes a loss if available information indicates that a loss
or range of losses is probable and reasonably estimable. The Company
estimates such losses on the basis of current facts and circumstances,
prior experience with similar matters, the number of claims and the
- 9 -
<PAGE>
<PAGE> 10
anticipated cost of administering, defending and, in some cases, settling
such claims. The Company has also recorded as an asset certain insurance
recoveries which are determined to be probable of occurrence on the basis
of the status of current discussions with its insurance carriers. If a
contingent loss is not probable but is reasonably possible, the Company
discloses this contingency in the notes to its consolidated financial
statements if it is material. Based on the information available, the
Company does not believe that reasonably possible uninsured losses in
excess of amounts recorded for the above matters of litigation would have
a material adverse impact on the Company's financial position or results
of operations.
- 10 -
<PAGE>
<PAGE> 11
ITEM 2.
RHONE-POULENC RORER INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS
AND FINANCIAL CONDITION
Rhone-Poulenc Rorer Inc. ("RPR" or "the Company") was formed by the
combination of Rorer Group Inc. (Rorer) and substantially all of the
Human Pharmaceutical Business of Rhone-Poulenc S.A. (RP) in July 1990.
Rhone-Poulenc Rorer is one of the largest research-based pharmaceutical
companies in the world. In the discussion which follows, percentage
comparisons of year-to-year sales, except when noted as reported sales,
exclude the effects of exchange rate fluctuations.
RESULTS OF OPERATIONS (First quarter 1994 versus first quarter 1993)
On sales of $871 million, net income available to common shareholders
was $74 million ($.54 per common share) compared with $94 million ($.68
per common share) for the year-ago quarter. Results included $4 million
($.02 per common share) pretax gains on the sale of certain assets and
product rights ($10 million or $.05 per common share in 1993).
The global pharmaceutical industry continues to be affected by
government initiatives in several countries to reduce pharmaceutical
prices and limit the volume of prescriptions written. The Company's
first quarter reported sales were down 5% from 1993. On a basis which
excludes the effects of currency fluctuations and product divestitures,
net sales were level with the prior year. Price decreases negatively
impacted the year-on-year change in sales by slightly more than one
percentage point.
Sales in the United States increased 15% to $213 million led by growth
of the Armour business and certain prescription pharmaceuticals.
Excluding the effects of currency fluctuations and product divestitures,
non-U.S. sales declined 8% in 1994. At $310 million, sales in France,
the Company's largest market, declined 11% on an operational basis due
to lower sales of anti-infectives and analgesics following an unusually
high incidence of influenza in the first and fourth quarters of 1993.
The Company's performance in Other Europe markets has been affected by
restrictive government programs and reduced prescription prices. In the
first quarter of 1994, Other Europe sales of $237 million improved 6% as
prescription pharmaceutical sales in Germany recovered by 17% from
depressed prior year levels. Prescription pharmaceutical sales in Italy
continue to be adversely impacted by government programs and declined
26% from the first quarter 1993. At $111 million, sales in the Rest of
World region were 3% below the prior year, reflecting trade buying
patterns in anticipation of an April 1st price reduction in Japan.
First quarter sales growth of plasma derivatives was led by U.S. sales
of AlbuminarR and sales of Monoclate-PR in Europe and the United States.
Cardiovascular products also experienced sales gains during the quarter
with U.S. sales of Dilacor XRR and LovenoxR, launched in the U.S. in the
second quarter 1993, leading the category.
Three-month sales of anti-infectives and analgesia products,
particularly DolipraneR, were below prior year levels following
unusually strong demand in France during the first and fourth quarters
of 1993.
The Company's hypersensitivity products, particularly AzmacortR,
- 11 -
<PAGE>
<PAGE> 12
experienced sales shortfalls during the quarter. Despite growth in
prescriptions, AzmacortR, and to a lesser extent, NasacortR, experienced
comparative declines in ex-factory sales in the U.S. due to trade
inventory buying patterns.
MaaloxR experienced lower first quarter 1994 sales as declines in the
U.S. and Canada more than offset increases in Other Europe markets,
particularly Germany. The Company's share of the highly competitive
U.S. antacid market trailed the prior year.
First quarter calcitonin sales were well below prior year levels due to
reduced government reimbursement in Italy, trade buying patterns in
anticipation of an April 1st price reduction in Japan, and generic
competition in the United States. The reimbursement status of
calcitonin in Italy has been appealed; no decision is expected until the
fourth quarter of 1994.
The Company strengthened its position in the area of oncology with the
launch of GranocyteR for chemotherapy-induced neutropenia in France,
Germany and several other markets during the quarter. The Company also
acquired the U.S. marketing rights to OncasparTM, manufactured by Enzon,
Inc. for use in the treatment of acute lymphoblastic leukemia.
OncasparTM is the first oncology drug to be marketed in the United States
by RPR. The Company is currently a partner in a joint venture with
Immune Response Corporation ("IRC") to develop an AIDS immunotherapeutic
vaccine. Certain issues regarding the joint and individual
responsibilities of RPR and IRC have recently been clarified through
arbitration proceedings.
For the three-month period, gross margin remained level with the prior
year as changes in product mix and price neutralized cost improvements.
At $130 million, operating income margin was approximately two
percentage points below the 1993 quarter. The benefit of lower selling
expenses due to previous sales force reductions was more than offset by
increased marketing expenses in Germany and the U.S. and higher research
and development expenditures as a percentage of sales. On a full year
basis, the Company's investment in research and development is expected
to approach $600 million.
Management is currently considering a restructuring program aimed at
streamlining worldwide manufacturing operations as well as selling,
marketing and administrative activities in selected markets. The
measures are intended to contribute to the broader objective to reduce
operating costs, exclusive of research and development. The cost of the
program, when recorded, will likely have a material impact on 1994
quarterly and annual results. Approval of the restructuring measures is
likely to occur during the second quarter.
Net interest expense declined 42% as a result of lower average net debt
balances and lower average interest rates particularly in Europe.
Preferred dividends were higher due to a net increase in outstanding
preferred shares and the effect on auction rate dividends of higher U.S.
short-term interest rates in the first quarter of 1994.
Other expense included losses of $5 million associated with the
Company's third quarter 1993 equity investment in Applied Immune
Sciences, Inc. ("AIS").
The Company records income tax expense based on an estimated full year
effective income tax rate. The first quarter estimated effective tax
rate was 29.1% and 29.2% in 1994 and 1993, respectively.
- 12 -
<PAGE>
<PAGE> 13
FINANCIAL CONDITION
Net cash provided by operating activities was $126 million for the first
quarter, representing a $35 million decrease versus the comparable prior
year period, reflecting lower earnings and higher cash outlays for
income taxes, partially offset by lower working capital needs.
Investing activities used cash of $58 million, including $44 million for
capital expenditures. Although lower in the 1994 first quarter, capital
expenditures for the full year are expected to approximate 1993 levels.
Cash used in financing activities decreased $46 million to $68 million
due to a lower level of debt repayments, offset in part by common share
repurchases and higher dividends. During the quarter, the Company
repurchased approximately one million of its common shares ($40 million)
for the Employee Benefits Trust to fund employee benefits in the U.S;
such share repurchases totaled $5 million in the first quarter 1993 when
the program was initiated. Dividends paid to common shareholders
totaled $38 million or $.28 per share, an increase of 27% per share from
the prior year period.
The Company's net debt (short- and long-term debt including notes
payable to RP, less cash and cash equivalents, short-term investments
and time deposits) to net debt plus equity ratio was .26 to 1 at March
31, 1994 and December 31, 1993. At March 31, 1994, the Company
classified approximately $350 million of notes payable as long-term debt
in accordance with the Company's intention and ability to refinance such
obligations on a long-term basis.
The Company had committed lines of credit totaling $1.4 billion on March
31, 1994 with no borrowings outstanding under these lines. Of this
amount, $700 million relates to a long-term revolving credit facility
unconditionally guaranteed by RP; the amount available reduces by $200
million per year until expiration of the facility in 1997. On April 30,
an additional $100 million of the facility expired. In a separate
agreement with RP, the Company has agreed to maintain as unused under
this facility the smaller of $325 million or the principal amount of
debt outstanding (excluding borrowings from, or guaranteed by, RP). The
Company has an additional $745 million available under several multi-
currency line of credit agreements expiring throughout the next five
years.
Pursuant to a shelf registration filed in 1993, the Company has the
ability to issue $325 million in debt securities or preferred shares.
At March 31, 1994, the ratio of current assets to current liabilities
was 1.51 to 1 compared with 1.37 to 1 at year-end due to the replacement
of short-term borrowings with RP by third party long-term borrowings.
Management believes that cash flows from operations, supplemented by
financing expected to be available from external sources, will provide
sufficient liquidity for the foreseeable future.
Long-term liquidity is dependent upon the Company's competitive
position, including its ability to adapt to the changing marketplace,
discover, develop and market innovative new therapies, and maximize the
benefits of new business alliances. In addition to its 1993
collaboration with AIS in the area of gene and cell therapy, the Company
recently entered into an alliance with Caremark International Inc., a
pharmaceutical benefit management company, to enhance the delivery of
cost-effective drug therapies.
- 13 -
<PAGE>
<PAGE> 14
On April 28, 1994, the Board of Directors declared a cash dividend of
$.28 per common share payable May 31, 1994 to shareholders of record May
10, 1994, an increase of 17% from the second quarter 1993.
The Company is involved in litigation incidental to its business. A
discussion of contingencies appears in Note 6 of the Notes to Condensed
Consolidated Financial Statements and in Legal Proceedings in Part II of
Form 10-Q.
- 14 -
<PAGE>
<PAGE> 15
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings
-----------------
Diethylstilbestrol ("DES") Litigation
- -------------------------------------
There are approximately two hundred legal actions pending against one or
more subsidiaries of the Company and various groupings of more than one
hundred pharmaceutical companies, in which it is generally alleged that
"DES daughters" and/or their offspring were injured as a result of the
development of various reproductive tract abnormalities in the "DES
daughters" because of their in utero exposure to DES. Typically,
William H. Rorer, Inc. ("WHR") and Kremers-Urban Company ("K-U"), two
former operating subsidiaries of the Company, are named as defendants,
along with numerous other former DES manufacturers, when the claimant is
unable to identify the manufacturer of the DES to which she was exposed.
While the aggregate monetary damages sought in all of these DES actions
are substantial, the Company believes that both WHR and K-U have
adequate defenses to DES claims. In May 1994, a proposed class action
was filed on behalf of persons alleging injuries caused by DES living in the
state of Ohio (Kurczi, et al. v. Eli Lilly, et al., United States District Court
for the Northern District of Illinois). The Company and certain of its
current and former subsidiaries were named among the 192 defendants. In
at least seven DES actions, plaintiffs have sought
certification of a class and have been unsuccessful. As the
facts of each individual lawsuit vary widely, the Company does not
believe that class action status is warranted and intends to vigorously
oppose this petition requesting class action certification. All pending
cases are currently being defended by insurance carriers, sometimes
under a reservation of rights. The Company is also responsible for the
obligations of Nattermann & Cie GmbH ("Nattermann") with respect to DES-
related legal actions brought against certain of its former U.S.
subsidiaries. Under the terms of the 1990 Acquisition Agreement with
Rhone-Poulenc S.A. (RP), RP is obligated to indemnify the Company for
amounts expended on the Nattermann DES claims in excess of $2 million.
The Company believes that the former Nattermann subsidiaries have
adequate defenses to DES claims.
AHF Litigation
- --------------
There are approximately one hundred seventy-nine pending lawsuits in the
United States, twenty-five in Canada and fifty-four in Ireland against
the Company's Armour Pharmaceutical Company ("Armour") subsidiary, the
Company's Plasma Alliance, Inc. subsidiary, and in some instances, the
Company, in which individuals with hemophilia and infected with the
Human Immunodeficiency Virus ("HIV"), or their representatives, claim
that their infection with HIV and, in some cases, resulting illnesses,
including Acquired Immune Deficiency Syndrome-related conditions or
death therefrom, may have been caused by administration of anti-
hemophilic factor ("AHF") concentrates processed by Armour in the early
and mid-1980's; none of these cases involves Armour's currently
distributed AHF concentrates. In most of these suits, Armour is one of
a number of defendants, including other fractionators who supplied AHF
during that period. To date, approximately sixty-three claims have been
resolved either by dismissal by the plaintiffs or the Court or through
settlement. A majority of the currently pending lawsuits were filed in
1993, and management believes the number of lawsuits filed will continue
to trend upward. It is not possible, however, to predict with certainty
the number of additional lawsuits that may eventually be filed alleging
HIV-related claims.
In January 1993, a jury in Florida held that Armour was liable to the
parents of a deceased HIV-infected hemophiliac for damages of
- 15 -
<PAGE>
<PAGE> 16
approximately $2 million. Armour believes this verdict to be
inconsistent with evidence specific to the case and, accordingly, it
filed motions with the trial court seeking reversal or, alternatively, a
new trial. The trial court has denied both motions. Armour has
appealed this judgment to the United States Court of Appeals for the
Eleventh Circuit. Regardless of the outcome of this case, and because
the facts vary widely in such cases, the Company does not view this
verdict as predictive of, or as precedent for, decisions in any other
cases. Juries in other AHF cases have determined that Armour and the
other plasma fractionators acted responsibly and were not negligent. In
October 1993, Armour obtained a directed verdict dismissing it from a
lawsuit pending in Louisiana State Court on the basis that the plaintiff
had not presented evidence sufficient to maintain an action against
Armour. Additionally, a jury verdict in favor of Armour and the other
plasma fractionators was obtained in an action pending in the United
States District Court for the Northern District of Illinois in November
1993. The jury concluded that the fractionators of Factor VIII
concentrate in the early 1980's were not negligent as alleged and
accordingly were not liable to the claimant. Plaintiff's post-trial
motion seeking a new trial was denied. Plaintiff recently appealed the
judgment to the United States Court of Appeals for the Seventh Circuit.
Although there are no other actions pending against Armour which are
presently at trial, three cases are presently set for trial in 1994 and
Armour reasonably expects that other cases will proceed to trial in the
future.
In December 1993, the Federal Multi-District Litigation Panel authorized
the consolidation of all AHF litigation pending in U.S. Federal Courts
for purposes of pre-trial discovery and the transfer of such cases to
the U.S. District Court for the Northern District of Illinois for this
purpose. As of March 1994, four proposed federal class action lawsuits
(Wadleigh, et al. v. Armour Pharmaceutical Company, et al., United
States District Court, Northern District, Illinois; Richard Roe and his
mother, Jane Roe v. Armour Pharmaceutical Company, et al., United States
District Court, Idaho District; Jose Alvarez, Jr. et al. v. Armour
Pharmaceutical Company, et al., United States District Court for the
Eastern District of Louisiana; and Timmy Dale Martin, et al. v. Armour
Pharmaceutical Company, et al., United States District Court for the
Northern District of Alabama; and one proposed state class action (D.K.,
L.K.; R.K., Sr., et al.; v. Armour Pharmaceutical Company, et al.,
Superior Court, Middlesex County, New Jersey), have been filed against
several fractionators, including Armour. As the facts in each
individual lawsuit vary widely, Armour does not believe that class
action status is warranted in any of these actions. Previously, two
U.S. Federal Courts and one State Court had denied petitions for class
action certification; most recently, in April 1994, the New Jersey
Superior Court denied permission to bring the above-mentioned state
class-action lawsuit. The Company intends to vigorously oppose the
remaining petitions requesting class action certification.
In the U.S., Armour and other plasma fractionators have participated in
discussions with representatives of the hemophilia community, including
the National Hemophilia Foundation, concerning the issue of assistance
for U.S. hemophiliacs infected with HIV. These discussions are not
active at this time. While Armour will continue to vigorously defend
its position in all cases and claims brought against it, the Company
will evaluate alternative ways of resolving pending and threatened
litigation.
The Company has contractual rights to certain insurance coverage
provided by insurance carriers to Revlon, Inc., the party from which it
- 16 -
<PAGE>
<PAGE> 17
purchased the Armour business in 1986 ("Revlon carriers"). The Company
also believes it has certain insurance coverage from another principal
insurance carrier ("principal carrier") and from an umbrella insurance
carrier. In addition, the Company believes it has access to "excess"
liability insurance coverage from other carriers, effective in 1986, for
certain of these cases if certain self-insured retention levels from
relevant insurable losses are exceeded. The Company has been involved
in litigation with the principal and umbrella carriers as well as with
certain of the Revlon carriers, relative to carrier defense and
indemnity obligations associated with AHF litigation. A trial in the
insurance coverage litigation, if necessary, would take place in the
United States District Court for the Eastern District of Pennsylvania
sometime in 1994. In August 1993, the Court granted the Company's
motion for partial summary judgment, deciding that the principal carrier
is obligated to provide a defense to the Company for the AHF litigation.
The Company and certain of the carriers are engaged in extensive
discussions aimed principally at settling the extent and other
conditions of coverage of those carriers. Based upon these discussions,
the Company believes that, although not a certainty, a substantial level
of coverage (including substantial coverage for legal defense
expenditures) for the Company's estimated liability determined in
accordance with Statement of Financial Accounting Standards No. 5 ("SFAS
5") is probable of occurrence.
Antitrust Litigation
- --------------------
The Company has been named as a defendant in six antitrust actions
pending in state and federal courts in Northern California, eleven in
Federal Court in the Southern District of New York, and single actions
in the District of Minnesota, the District of South Carolina, the
Southern District of Ohio, the Southern District of Georgia, and in
state court in Alabama. The suits allege that RPR, certain other
pharmaceutical companies and wholesalers and a large mail order concern
discriminated against independent community pharmacist plaintiffs with
respect to the prices charged for pharmaceutical products and further
conspired to maintain prices at artificially high levels to the
detriment of these pharmacies. Most of the federal actions purport to
be class actions, as do four of the five state cases. Plaintiffs in
these lawsuits seek injunctive relief and a monetary award for past
damages alleged. The federal class plaintiffs have filed an amended
consolidated Complaint so that issues affecting the class are
consistently pleaded.
The Judicial Panel on Multi-District Litigation has consolidated federal
cases in which the Company is a named defendant with several other
related federal actions in which the Company is not named as a defendant
for purposes of coordinating overlapping pre-trial proceedings, such as
discovery. The cases have been coordinated in the Northern District of
Illinois. Similarly, the five state cases in which the Company is named
have been coordinated with four other cases in which the Company is not
named as a defendant in the Superior Court for the County of San
Francisco.
While the aforementioned cases are in their early stages, the Company
believes that the claims are without merit and it intends to vigorously
defend these lawsuits.
Patent and Intellectual Property Litigation
- -------------------------------------------
The Company is a plaintiff in a patent infringement lawsuit with Chiron
Corporation filed in the United States District Court in California
involving the patent licensed exclusively to the Company by the Scripps
Research Institute ("Scripps") covering the antihemophilic Factor
- 17 -
<PAGE>
<PAGE> 18
VIII:C. The Court is considering pending summary judgment motions. If
this case goes to trial, such trial is likely to be scheduled to
commence within the next six to twelve months.
In February 1993, Tanabe Seiyaku Company ("Tanabe") of Japan and their
U.S. licensee, Marion Merrell Dow Inc. ("MMD") initiated an action
before the International Trade Commission ("ITC"), the administrative
agency responsible for handling complaints of imports which allegedly
infringe U.S. patent rights. The complaint names ten domestic and
foreign respondents, including the Company, and alleges infringement of
a Tanabe U.S. patent, claiming a process for preparing bulk diltiazem,
the active ingredient in the Company's Dilacor XRR product. Tanabe and
MMD are requesting relief in the form of an Exclusion Order and a Cease
and Desist Order. The Company has raised several defenses, including
lack of jurisdiction, patent invalidity, and non-infringement. The ITC
has suspended the proceeding indefinitely in view of an ongoing
reexamination proceeding involving the Tanabe U.S. process patent.
The eventual outcomes of the above matters of pending litigation cannot
be predicted with certainty. The defense of these matters and the
defense of expected additional lawsuits related to these matters may
require substantial legal defense expenditures. The Company follows
SFAS 5 in determining whether to recognize losses and accrue liabilities
relating to such matters. Accordingly, the Company recognizes a loss if
available information indicates that a loss or range of losses is
probable and reasonably estimable. The Company estimates such losses on
the basis of current facts and circumstances, prior experience with
similar matters, the number of claims and the anticipated cost of
administering, defending and, in some cases, settling such claims. The
Company has also recorded as an asset insurance recoveries which are
determined to be probable of occurrence on the basis of the status of
current discussions with its insurance carriers. If a contingent loss
is not probable, but is reasonably possible, the Company discloses this
contingency in the notes to its consolidated financial statements if it
is material. Based on the information available, the Company does not
believe that reasonably possible uninsured losses in excess of amounts
recorded for the above matters of litigation would have a material
adverse impact on the Company's financial position or results of
operations.
- 18 -
<PAGE>
<PAGE> 19
ITEM 4. Submission of Matters to a Vote of Security Holders
----------------------------------------------------
At the Annual Meeting of Shareholders held on April 28, 1994, the four
nominees to the Board of Directors were elected to three-year terms
ending in 1997 and the selection of independent accountants for 1994 was
ratified.
ITEM 6. Exhibits and Reports on Form 8-K
---------------------------------
a. Exhibits
10 Material contracts:
a.Employment Agreement with Robert E. Cawthorn,
dated March 18, 1994.
b.Rhone-Poulenc Rorer Senior Partner Long-Term
Capital Plan, effective January 1, 1994.
c.Rhone-Poulenc Rorer Inc. Executive Deferral
Plan, effective December 1, 1993.
11 Statement re computation of earnings per common share.
15 Letter re unaudited interim financial information.
b. Reports on Form 8-K
The Company did not file any Current Reports on Form 8-K during the
quarter for which this report is filed.
- 19 -
<PAGE>
<PAGE> 20
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
RHONE-POULENC RORER INC.
-----------------------------------------------
(Registrant)
May 13, 1994 /s/PATRICK LANGLOIS
-------------- -----------------------------------------------
Patrick Langlois
Senior Vice President and
Chief Financial Officer
May 13, 1994 /s/DANIEL J. PEDRIANI
-------------- -----------------------------------------------
Daniel J. Pedriani
Vice President-Corporate Controller
Chief Accounting Officer
- 20 -
<PAGE>
<PAGE> 21
INDEX TO EXHIBITS
Exhibit No. Page
- ------------- ------
10 Material contracts:
a.Employment Agreement with Robert
E. Cawthorn, dated March 18, 1994. 22
b.Rhone-Poulenc Rorer Senior Partner
Long-Term Capital Plan, effective
January 1, 1994. 27
c.Rhone-Poulenc Rorer Inc. Executive
Deferral Plan, effective
December 1, 1993. 43
11 Statement re computation of earnings
per common share. 53
15 Letter re unaudited interim financial
information. 54
- 21 -
<PAGE>
<PAGE> 22
EXHIBIT 10a.
Rhone-Poulenc Rorer Inc.
500 Arcola Road
P.O. Box 1200
Collegeville, PA 19426-0107
Mr. Robert E. Cawthorn March 18, 1994
50 Crosby Brown Road
Gladwyne, PA 19035
Employment Agreement
----------------------
Dear Mr. Cawthorn:
This letter agreement (the "Agreement") sets forth our understanding
concerning the terms of your continued employment with RHONE-POULENC
RORER INC. (the "Company") during the employment period (as defined
below).
1. Prior Agreements. Except as otherwise specifically provided
herein, effective as of May 5, 1994, this Agreement amends and
restates in full the employment agreement between you and the
Company, dated March 12, 1990, as amended (the "Prior Agreement"),
and the letter agreement between you and the Company, dated March
12, 1990, describing certain methodologies and referred to in the
Prior Agreement (the "Letter Agreement"). During the period
between the date hereof and May 5, 1994, the Prior Agreement and
the Letter Agreement shall govern the terms and conditions of your
employment with the Company, provided, however, that Paragraphs 3,
11(a), 11(b), 12(a) and 12(b) of the Prior Agreement shall not
apply after the date hereof and the employment term under the Prior
Agreement shall terminate as of May 4, 1994 by our mutual consent
and without any liability of the Company to you for severance or
otherwise.
2. Employment Period. The period of your employment here-under will
commence on May 5, 1994 and end on May 4, 1995, provided, however,
that (i) your employment here-under will be automatically extended
for one (1) year on each May 5th unless either you or the Company
shall have given ninety (90) days' prior written notice to the
other of a desire that such automatic extension not occur and (ii)
your employment hereunder will automatically terminate upon your
resignation as Chief Executive Officer of the Company.
1
- 22 -
<PAGE>
<PAGE> 23
3. Position and Duties. During the employment period, you will serve
as Chairman of the Board of Directors and Chief Executive Officer
of the Company, which are the positions you currently hold, having
relinquished the position of President in 1991. You will have such
responsibilities, duties and authority as you have as of the date
hereof in your positions as Chairman and Chief Executive Officer of
the Company. You agree to serve without additional compensation,
if elected or appointed thereto, as a director of any of the
Company's subsidiaries and in one or more executive offices of any
of the Company's subsidiaries, provided that you are indemnified
for serving in any and all capacities by the Company on a basis no
less favorable than is provided by the Company to you with respect
to your services to the Company, except as may be limited by
applicable law. Effective on the last day of the employment
period, you will be deemed to have resigned from all positions,
directorships and offices you then hold with the Company or any of
its subsidiaries, unless the Company will have requested and you
will have agreed to continue to serve in such capacity.
4. Compensation.
a. Amount. In consideration for your services under this
Agreement, your cash compensation for the employment period
will consist of salary at the rate of your 1994 Salary and
your 1994 Bonus. "1994 Salary" means the annual rate of
salary for the twelve-month period commencing on March 15,
1994 determined in accordance with Paragraph 5 of the Prior
Agreement. "1994 Bonus" means the bonus payable to you for
the period January 1, 1994 through December 31, 1994
determined in accordance with Paragraph 6 of the Prior
Agreement.
b. Time of Payment. Your compensation will be paid to you in the
following manner:
i.You will be paid base salary semi-monthly in arrears at
the 1994 Salary annual rate.
ii.Not later than March 15, 1995, you will be paid an
amount equal to your 1994 Bonus; provided, however, that
upon any termination of your employment prior to
December 31, 1994 due to your resignation as Chief
Executive Officer of the Company, the amount of your
1994 Bonus shall be reduced to an amount proportionate
to the actual number of days during the bonus period in
which you served as Chief Executive Officer and such
reduced 1994 Bonus will be paid to you within ten (10)
days of such resignation.
2
- 23 -
<PAGE>
<PAGE> 24
c. Lump-sum Payment upon Termination. On the day after the last
day of the employment period (as the same may be extended), you
will be paid a lump-sum amount equal to one times the 1994
Salary and 1994 Bonus (on a full year basis).
5. Equity Compensation. No later than March 15, 1995, and provided
that at such time you hold your position as Chief Executive
Officer, the Company will grant you stock options for shares of
common stock of the Company in an amount determined in accordance
with Paragraph 8(b) of the Prior Agreement and on such other terms
as provided to other senior executives. Upon the later of
termination of your position as Chief Executive Officer or May 4,
1995, (a) any restrictions on any restricted shares you then hold
will lapse, (b) any vested stock options you then hold and such
additional stock options that would be vested as of such date if
you had continued in employment through such date will be
exercisable for a period of five (5) years following such date (it
being understood that any vested stock options the ten year term of
which would normally expire at any time prior to the end of such
five year period shall expire at such normal time), and (c) any
unvested stock options you then hold will automatically expire.
6. Benefits. During the employment period, you will be entitled to
the same benefits to which you are entitled under Paragraph 9 of
the Prior Agreement.
7. Unauthorized Disclosure. During the employment period and for five
years thereafter, except as necessary or appropriate in the
performance of your duties under this Agreement, you will not
directly or indirectly disclose (except as otherwise required by a
court or governmental agency) or use any trade secret or
confidential information you obtained while in the employ of the
Company with respect to any of the products, improvements,
formulas, processes, customers, methods of distribution or methods
of manufacture of the Company or any of its subsidiaries or
affiliates, provided, however, that trade secrets and confidential
information will not include any information known generally to the
public or in the industry or industries in which the Company is
involved (other than as a result of unauthorized disclosure by
you).
3
- 24 -
<PAGE>
<PAGE> 25
8. Noncompetition. During the employment period and for one year
thereafter you will not directly or indirectly engage or
participate in, as an owner, investor, partner, shareholder,
officer, employee, director, agent or consultant, any business
which directly or indirectly competes with the Company or any of
its subsidiaries or affiliates (other than through the ownership of
not more than five percent of the voting stock of any corporation).
9. Miscellaneous.
a. Notices. All notices and communications required or permitted
to be given hereunder shall be duly given delivering the same
in hand or by depositing such notice or communication in the
mail, sent by certified or registered mail, return receipt
requested, postage prepaid, or by delivery by overnight
courier, with a receipt obtained therefore, as follows:
If sent to the Company: RHONE-POULENC RORER INC.
500 Arcola Road
P.O. Box 1200
Collegeville, PA 19426-0107
Attn: General Counsel
with copy to: RHONE-POULENC S.A.
25, quai Paul Doumer
92408 Courbevoie Cedex
FRANCE
Attn: Directeur des Affaires
Juridiques et des Accords
If sent to you: 50 Crosby Brown Road
Gladwyne, PA 19035
or such other address as either party furnished to the other by like
notice.
a. Tax Withholding. All amounts paid to you hereunder will be subject
to applicable federal, state and local tax withholding.
b. Amendment. This Agreement may be amended only by a written
document signed by the parties hereto.
c. Governing Law. This Agreement will be governed by, and construed
in accordance with, the law of the Commonwealth of Pennsylvania.
4
- 25 -
<PAGE>
<PAGE> 26
d. Counterparts. This Agreement may be executed in any number of
counterparts, each executed counterpart constituting an original
and such counterparts together constituting one agreement.
If you agree with the terms of your employment as set forth in this
Agreement, please execute the duplicate copy hereof in the space
provided below.
RHONE-POULENC RORER INC.
By /s/ David A. Brandies
-----------------------
Vice President
ACCEPTED AND AGREED:
- ----------------------
By /s/ Robert E. Cawthorn
-----------------------
Robert E. Cawthorn
ACKNOWLEDGED AND CONSENTED TO:
RHONE-POULENC S.A.
By /s/ Jean-Marc Bruel
--------------------
Jean-Marc Bruel
5
- 26 -
<PAGE>
<PAGE> 27
EXHIBIT 10b.
RHONE-POULENC RORER
SENIOR PARTNER LONG TERM CAPITAL PLAN
- 27 -
<PAGE>
<PAGE> 28
TABLE OF CONTENTS
-------------------
Article Subject Matter Page
- -----------------------------------------------------------------------------
I Purpose of the Plan 2
II Definitions 2
III Administration 3
IV Participation 4
V Awards 4
VI Accounts 6
VII Vesting 7
VIII Distribution of Account 7
IX Death Benefits 10
X Amendment and Termination 10
XI Miscellaneous 10
1
- 28 -
<PAGE>
<PAGE> 29
PURPOSE OF THE PLAN
------------------------
1.1Purpose. The purpose of the Rhone-Poulenc Rorer Senior Partner Long
Term Capital Plan (the "Plan"), as set forth herein and as the same may
hereafter be amended, is to provide performance incentives to certain designated
executives of Rhone-Poulenc Rorer Inc.("RPR") who have made, and who it is
anticipated will continue to make, contributions that are instrumental to
the success of RPR and its affiliates (hereinafter collectively referred to as
the "Company"). It is the intent of the Company that "Notional Shares" be
awarded, based on certain Company financial results, and allocated to accounts
for designated participants in the Plan to enable them to receive benefits
based upon the financial performance of the Company.
ARTICLE II
DEFINITIONS
-------------
2.1"Account" means a bookkeeping account established under the Plan with
respect to a Senior Partner which reflects the number of Notional Shares
standing to the credit of the Senior Partner under the Plan and the value
thereof. A Senior Partner's Account shall consist of a "Long-Term Account"
and a "Short-Term Account".
2.2"Award" means an award under Article V hereof to be converted to
Notional Shares and credited to a Senior Partner's Account.
2.3"Award Date" means the date an Award is credited to a Senior Partner's
Account.
2.4"Base Salary" means the annual amount of base salary and wages paid
by the Company to an Employee for any calendar year of employment including
elective deferrals under IRC Sections 125 and 401(k).
2.5"Board" means the Board of Directors of RPR.
2.5[sic]"Committee" means the Executive Personnel and Compensation
Committee of the Board which shall perform specified duties with respect to
the Plan.
2.6"Effective Date" means January 1, 1994.
2.7"Employee" means any individual employed by the Company.
2
- 29 -
<PAGE>
<PAGE> 30
2.8"Notional Share" means a single unit credited to the Account of a
Senior Partner which shall be deemed to be equal in value to one share of the
common stock of RPR.
2.9"Plan" means the Rhone-Poulenc Rorer Inc. Senior Partner Long Term
Capital Plan, as the same is set forth herein, and as it may be amended from
time to time.
2.10"Senior Partner" means any Employee who is an executive of the Company
(Grade 46 or above) and who is designated as a Senior Partner by RPR's Executive
Council. The status of an Employee as a Senior Partner shall terminate on the
first to occur of (i) the date specified by the Executive Council (which shall
not be retroactive without the written consent of the Employee) or (ii) the
date on which the Senior Partner Separates from Employment.
2.11"Separates from Employment" means the Employee's termination of
employment from the Company. Except as otherwise provided herein, a Separation
from Employment shall be deemed to have occurred on the last day of the
Employee's service to the Company and shall be determined without reference to
any compensation continuation arrangement or severance benefit arrangement
that may be applicable.
ARTICLE III
ADMINISTRATION
----------------
3.1Administration. The Plan shall be administered by the Committee which
shall have full power and authority to interpret the Plan, to prescribe, amend
and rescind any rules, forms and procedures as it deems necessary or
appropriate for the proper administration of the Plan and to make any other
determinations, including factual determinations, and to take any other such
actions as it deems necessary or advisable in carrying out its duties under
the Plan. All action taken by the Committee arising out of, or in connection
with, the administration of the Plan
or any rules adopted thereunder, shall, in each case, lie within its sole
discretion, need not be uniform as to similarly situated persons and shall be
final, conclusive and binding upon the Company, the Board, all Employees, all
beneficiaries of Employees and all persons and entities having an interest
therein.
3.2Expenses. Members of the Committee shall serve without compensation
for their services under the Plan unless otherwise determined by the Board.
All expenses of administering the Plan shall be paid by the Company.
3.3Indemnification. The Company shall indemnify and hold harmless each
member of the Committee from any and all claims, losses, damages, expenses
(including counsel
3
- 30 -
<PAGE>
<PAGE> 31
fees) and liability (including any amounts paid in settlement of any claim or
any other matter with the consent of the Board) arising from any act or omission
of such member, except when the same is due to gross negligence or willful
misconduct.
ARTICLE IV
PARTICIPATION
---------------
4.1Eligibility. All Senior Partners shall be eligible to participate in
the Plan. Designation as a Senior Partner does not constitute an Award. No
Award may be made to an Employee or former Employee on or after ceasing to be
a Senior Partner (unless such Employee has subsequently resumed Senior
Partner status).
ARTICLE V
AWARDS
--------
5.1Performance Period. The Committee shall establish and announce
a measurement period over which the performance of the Company shall be
determined (the "Performance Period"). The initial Performance Period shall be
a period of three years commencing on January 1, 1994. Unless the Committee
determines and announces otherwise, succeeding Performance Periods shall be
three-year periods commencing on each January 1 thereafter.
5.2Determination of Award.
(a)Awards under the Plan for each Performance Period shall be based on the
Company's economic performance during the applicable Performance Period (the
"Corporate Goals") in relation to similar performance by a group of companies
deemed by the Committee to be comparable in the industry. The Corporate Goals,
a list of comparable companies and a calculation methodology from which to
determine the amount of any Award for a Performance Period based on the level
of Corporate Goals attained for that Performance Period are attached hereto,
and incorporated herein, as Exhibit A.
(b)At the end of each Performance Period, the Committee shall determine
how the Company has performed in relation to the Corporate Goals. If the
Company's performance during a Performance Period is sufficient to warrant the
granting of Awards, the amount of Award for each Senior Partner, as calculated
in accordance with Exhibit A, shall be a uniform percentage of the Senior
Partner's Base Salary paid in the final year of the Performance Period;
provided, however, that the maximum Award for any Performance Period shall not
exceed 50% of such Base Salary.
4
- 31 -
<PAGE>
<PAGE> 32
(c)In the event that the Company has not met the Corporate Goals set by
the Committee for a Performance Period, a reduction in each Senior Partner's
Account shall be made, as calculated in accordance with Exhibit A, in a uniform
percentage of each Senior Partner's Base Salary, as determined by the Committee,
but not to exceed 50% of the amount of the Senior Partner's Base Salary paid
in the final year of the Performance Period; provided, however, that no such
reduction may be applied against the Senior Partner's Kick-off Award,
pursuant to Section 5.3 hereof.
5.3Kick-off Award. Each Senior Partner on the Effective Date shall
receive an initial award as of such date (the "Kick-off Award") equal to 25% of
the Senior Partner's then current Base Salary. Each other Senior Partner shall
receive a Kick-off Award upon becoming a Senior Partner in the same
percentage although such Award may be taken into account in determining the
amount of stock options or restricted stock granted to such Senior Partner under
the Company's long term incentive program.
5.4Notification. Each Senior Partner shall be notified in writing of
each Award and to the extent that any Award shall be subject to terms,
conditions and limitations not set forth in the Plan, the Senior Partner
shall be advised of such terms, conditions and limitations.
5.5Ownership Requirement. Notwithstanding anything in this Plan to the
contrary, and subject to the provisions of subsection (b) below, no Award shall
be made to any Senior Partner (and lost Awards shall not be restored) at any
time that the Senior Partner does not beneficially own a number of shares of
common stock of RPR equal in value to at least one year of the Senior Partner's
Base Salary as determined on January 1 of each year; provided, however, that
until the expiration of the time period as applicable to the Senior Partner
under subsection (b) below, the requirement shall be based upon the Senior
Partner's Base Salary as of January 1, 1994. For the purposes hereof:
(a) a Senior Partner shall be deemed to own shares of RPR common stock
equal to the number of Notional Shares credited to the Senior Partner's Account
under the Plan at any time (including shares attributable to the Kick-off
Award) and for each share of RPR common stock owned outside the Plan;
provided, however, that shares subject to an option shall not be deemed to be
beneficially owned until the option is exercised and the shares subject
thereto are actually issued to the Senior Partner; and
(b)a Senior Partner shall have the following amount of time (and Awards
shall not be lost during this period) following designation as a Senior Partner
(whether on or after the Effective Date) to meet the ownership requirement
depending upon the Senior Partner's assigned
5
- 32 -
<PAGE>
<PAGE> 33
participation level, applied by the Committee, as follows:
Time Period to
Senior Partner Satisfy Requirement after
Participation Level Becoming Senior Partner
---------------------------------------------------------------------------
1 2 years
2 2 years
3 2 years
4 3 years
5 3 years
6 4 years
ARTICLE VI
ACCOUNTS
----------
6.1Establishment. The Committee shall cause the Company to establish an
Account for each Senior Partner on the Company's books and shall cause an
allocation to each such Account of the number of Notional Shares credited to
the Senior Partner by reason of each Award under Article V hereof. Each Award
(or reduction), under Section 5.2 hereof, shall be credited (or debited) 50%
to the Senior Partner's Long-Term Account and 50% to the Senior Partner's
Short-Term Account. The Notional Shares attributable to a Senior Partner's
Kick-off Award shall be credited to the Senior Partner's Long-Term Account
but shall be accounted for separately thereunder until the Senior Partner's
right to those Notional Shares is fully vested in accordance with the
provisions of Section 7.2 hereof.
6.2Determination of Number of Notional Shares. The amount of each Award
shall be converted to Notional Shares by dividing the amount of the Award by
the value of one share of RPR common stock on the Award Date. The value of a
share of RPR common stock shall be the closing price of such shares on
the principal stock exchange on which the shares are traded on the Award
Date or, if not so traded, as determined by the Committee.
6.3Valuation and Reporting. A valuation of the Notional Shares shall
be made on an annual basis as of December 31 of each year and each Employee who
is, or who was, a Senior Partner shall receive a statement as to the number of
Notional Shares credited to the Employee's Account and the value thereof as
soon as practicable following that date.
6
- 33 -
<PAGE>
<PAGE> 34
ARTICLE VII
VESTING
----------
7.1General Rule. Except as provided in Section 7.2 hereof, each Employee
shall at all times be fully vested in the value of the Employee's Account;
provided, however, that the Employee's right to an amount to be distributed
from the Account may be reduced pursuant to the provisions of Section 5.2(c)
hereof.
7.2Vesting of Kick-off Award. The Kick-off Award shall vest ratably over
the six year period beginning on January 1, 1994 so that each Senior Partner
receiving a Kick-off Award shall have a vested interest in 16 2\3% of the value
of the Kick-off Award for each year of continued employment commencing on the
Effective Date and shall have a fully vested right to the Kick-off Award
on December 31, 1999. Notwithstanding the foregoing, an Employee shall also
have a fully vested right to the Kick-off Award if the Employee Separates from
Employment on account of death, disability that qualifies the Employee for
benefits under the Company's long term disability plan ("Disability"), or
retirement pursuant to a qualified retirement plan of the Company.
7.3Termination of the Plan or Change of Control. In the event that the
Plan is terminated by action of the Board pursuant to Article X hereof or there
occurs a Change of Control of RPR, 100% of all Awards credited to the
Employee's Account shall be fully and immediately vested. For the purposes
hereof, a "Change of Control" shall be deemed to have occurred if Rhone-
Poulenc S.A. and its Affiliates (as used herein, the term "Affiliates" shall be
deemed to include any corporation, joint venture, or other business enterprise,
whether incorporated or unincorporated, which Rhone-Poulenc S.A. directly, or
indirectly through one or more intermediaries, controls or is controlled by, or
is under common control with) cease to be the beneficial owners (as such term
is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934,
as amended) of securities of RPR representing more than fifty percent (50%)
of the combined voting power of RPR's then outstanding securities.
ARTICLE VIII
DISTRIBUTION OF ACCOUNT
-------------------------
8.1General Requirements. Cash shall be distributed under the Plan in
respect of the value of the Notional Shares credited to an Employee's Account
unless the Committee determines to make all or a portion of such distribution
in an equivalent number of shares of RPR common stock. No distribution may
take place prior to six months following the relevant Award Date of the Notional
Shares as to which the amount to be distributed is attributable. All payments
shall be made in the form of a single distribution; provided, however, that
the Committee may
7
- 34 -
<PAGE>
<PAGE> 35
determine to make the payment due hereunder in any year in the form of equal
annual installments which shall be payable over a ten-year period if the Com-
mittee believe that a lump sum payment would create a hardship to the Company.
If the Committee elects to make the payments hereunder in the form of install-
ments, interest shall be credited on the unpaid balance in an amount equal to
the lowest rate necessary to avoid imputed or unstated interest under the
applicable provisions of the Internal Revenue Code of 1986, as amended, or
the relevant statute in effect at the time.
8.2Short-Term Account.
(a)Unless the Senior Partner elects otherwise under subsection (b), the
value of Notional Shares credited to the Senior Partner's Short-Term Account
shall be distributed in three annual installments made within thirty
days following the end of each of the first three years following the close of
each Performance Period resulting in an allocation of such Notional Shares
to that Account based on the value of the number of Notional Shares being
distributed on each date (but subject to any reduction mandated by Section
5.2(c) hereof).
(b) A Senior Partner may make a written election, in the manner and in
the form prescribed by the Committee, to defer the receipt of the value of the
Notional Shares credited to the Senior Partner's Short-Term Account for any
Performance Period by making such election at any time prior to the close of
the relevant Performance Period. Any such election shall become irrevocable
as of the last day of such Performance Period and shall remain in effect for all
subsequent Performance Periods until revoked in writing prior to the close
of the then current Performance Period. In the event of such an election, the
distribution of the value of the Senior Partner's Short-Term Account
attributable to such Performance Period shall be determined and
distributed at the same time as the value of the Senior Partner's Long-Term
Account attributable to that Performance Period.
8.3Long-Term Account.
(a)Unless the Senior Partner elects otherwise under subsection (b), the
value of Notional Shares credited to the Senior Partner's Long-Term Account
shall be distributed in one lump sum made within thirty days following the
Senior Partner's 60th birthday and within thirty days of the close of each
subsequent fiscal year of RPR based on the value of the number of Notional
Shares being distributed on each date (but subject to any reduction mandated
by Section 5.2(c) hereof).
(b)A Senior Partner may make a written election, in the manner and in
the form prescribed by the Committee, to defer the receipt of the value
of the Notional Shares credited to the Senior Partner's Long-Term Account for
any Performance Period by making such election at any time prior to the
close of the relevant Performance Period. Any such election shall become
8
- 35 -
<PAGE>
<PAGE> 36
irrevocable as of the last day of such Performance Period. In the event of such
an election, the distribution of the value of the Senior Partner's Long-Term
Account attributable to such Performance Period shall be determined and
distributed within 60 days following the Senior Partner's Separation from
Employment.
8.3Separation from Employment Prior to Age 60. In the event of an
Employee's Separation from Employment prior to the attainment of age 60, the
Employee's Short-Term Account shall be liquidated and the value thereof
distributed within 60 days after the effective date of the Employee's
Separation from Employment. The value of the Employee's Long-Term Account
shall be frozen and an amount equal to such value shall be distributed to
the former Employee within 60 days after that individual's 60th birthday.
8.4Termination of Plan. Notwithstanding the provisions of Sections 8.2
and 8.3 hereof, in the event that the Plan is terminated by action of the Board
pursuant to Article X, all Notional Shares may be liquidated at the direction
of the Committee at any time after the expiration of sixty days after the date
of termination and the value of the Employee's Account distributed at that time.
8.5Separation from Employment for Cause. Notwithstanding anything herein
to the contrary, no payments shall be made under the Plan on or after the date
that the Committee determines that an Employee's Separation from Employment
was for "Cause," whether or not such determination is made before payments
commence hereunder. For the purposes hereof, "Cause" shall include (i) the
willful failure by the Employee to substantially perform his duties other
than by reason of Disability, (ii) the willful engaging by the Employee in gross
misconduct materially injurious to the Company, (iii) or the willful disclosure
by the Employee of confidential information of the Company which results in
material injury to the Company.
8.6Hardship Withdrawal. In the event the Senior Partner incurs a
significant financial hardship while employed by the Company, as determined by
the Committee, the Senior Partner may apply, in writing, for a withdrawal from
that portion of the Senior Partner's Short-Term Account or Long-Term Account
attributable to Awards the distribution of which has been deferred pursuant
to the provisions of Subsections 8.2(b) or 8.3(b) hereof. The Committee shall
determine whether to permit such a withdrawal and, based upon the Senior
Partner's application, the amount necessary to satisfy that hardship, which
shall be distributed in a single sum as soon as practicable after the
Committee's determination.
9
- 36 -
<PAGE>
<PAGE> 37
ARTICLE IX
DEATH BENEFITS
----------------
9.1Death of an Active Employee. In the event of the death of an Employee
while employed by the Company, who is, or who was, a Senior Partner, the
Employee's beneficiary as designated under the Company's group term
life insurance plan or other statutory plan of insurance, as applicable,
shall receive any payments due. The value of the Employee's Account
shall be liquidated within 60 days after the Employee's death. The cash
resulting from such liquidation shall be distributed in the form of a lump
sum in cash to the designated beneficiary, or, in the event that there is no
designated beneficiary, to the Employee's estate.
9.2Death after Separation from Employment. In the event of the death of a
former Senior Partner after a Separation from Employment, the portion of the
individual's Account that has not yet been liquidated shall be distributed in
the form of a lump sum to the designated beneficiary, or, in the event that
there is no designated beneficiary, to the former Employee's estate within
60 days of death or the date the former Employee would have attained
the age of 60, if later.
ARTICLE X
AMENDMENT AND TERMINATION
---------------------------
10.1Amendment. The Plan and any Awards issued thereunder may be amended
by the Committee at any time and from time to time all without prior notice to
any person or entity; provided, however, that no such amendment shall have the
effect of divesting an Employee of the Employee's interest in any Award
already made or allocated to the Employee's Account.
10.2Termination. Continuance of the Plan is completely voluntary and
is not assumed as a contractual obligation of the Company. The Committee,
acting on behalf of the Company, shall have the right to terminate the Plan in
whole or in part at any time without prior notice to any person or entity;
provided, however, that such termination shall not have the effect
of divesting an Employee of the Employee's interest in any Award already
made or allocated to the Employee's Account.
ARTICLE XI
MISCELLANEOUS
----------------
11.1No Obligation as to Employment. The Company is not, by reason of this
Plan, obligated to continue to employ any Employee in any employment capacity
nor shall any portion of this Plan effect in any way the right or power of the
Company to determine any Employee's employment with the Company.
10
- 37 -
<PAGE>
<PAGE> 38
11.2No Rights as Shareholder. No Employee shall have any rights as a
shareholder of RPR, including the right to any cash dividends or other
distributions, as the result of a grant to him of any Award or the crediting
of any Notional Shares to the Employee's Account.
11.3Any amounts payable hereunder shall not be deemed salary or other
compensation to an Employee for the purposes of computing benefits to which the
Employee may be entitled under any other arrangement established by the Company
for the benefit of its employees.
11.4Controlling Law. The provisions of the Plan shall be construed and
applied under the laws of the Commonwealth of Pennsylvania.
11.5Senior Partner's Rights Unsecured. The right of any Employee or of
the beneficiary of any Employee to receive a distribution or payment under
the Plan shall be an unsecured claim against the general assets of the Company.
Title to and beneficial ownership of any assets, whether cash or investments
which the Company may set aside or earmark to meet its deferred obligation
hereunder, shall at all times remain in the Company; and no Employee or
beneficiary shall under any circumstances acquire any property interest in
any specific assets of the Company. Title to any assets set aside in trust
by the Company shall be in the trustee of the trust for the benefit of the
Company.
11.6Severability of Provisions. If any provision of the Plan shall be
held invalid or unenforceable, such invalidity or unenforceability shall
not effect any other provisions hereof and the Plan shall be construed and
enforced as if such provisions had not been included.
11.7Headings and Captions. The headings and captions herein are provided
for convenience only, and shall not be construed as part of the Plan, and shall
not be employed in the construction of the Plan.
11.8Gender and Number. Except where otherwise clearly indicated by the
context, any gender specific word used in the Plan shall apply equally to
the opposite gender, the singular shall include the plural and the plural
shall include the singular.
11.9Payments to Incapacitated Payees. Any benefit payable to or for the
benefit of a payee who is a minor, an incompetent person, or is otherwise
incapable of receipting therefore shall be deemed paid when paid to such
person's guardian or to the party providing, or a reasonably appearing to
provide, the care for such person, and such payment shall fully
discharge the Company, the Committee, the Board and all other parties
with respect thereto.
11.10 Alienation. The rights of any Employee under this Plan are personal
and may not be assigned, transferred, pledged or encumbered. Any attempt to do
so shall be void.
11
- 38 -
<PAGE>
<PAGE> 39
Exhibit A
I. Corporate Goals - Net Income Performance:
Net income is "net income" as reported in RPR's annual published
income statement on Form 10-K, but reduced by the following items which are
disclosed in that financial statement or footnotes thereto:
- restructuring charges, net of tax;
- after-tax gain or loss on disposal of a business segment (i.e., gain or
loss from the sale/disposal transaction itself excluding the profit or
loss from operation of the segment during the period) which is disclosed
in a footnote to the financial statement;
- after-tax cost or benefit from changes in accounting principle or estimate
which are disclosed in a footnote to the financial statement;
- after-tax gain or loss reported as an "extraordinary item" in an accounting
sense; and
- other clearly significant and unusual one-time costs or benefits, net of
tax, which are disclosed in a footnote (example: the 1993 receipt by RPR
of $105 million proceeds from litigation settlement).
At the end of each three-year Performance Period, RPR will measure the
percentage of its growth in Net Income. This result will be measured against
the average percentage of growth in Net Income of companies in the Dow Jones'
pharmaceutical index. The result will determine whether an Award is due (or
a reduction is to be made) under the Plan.
12
- 39 -
<PAGE>
<PAGE> 40
II. Comparable Companies:
The following companies will be used to measure against RPR's percentage growth
in Net Income:
American Home Products
Bristol-Myers Squibb
Eli Lilly
Johnson & Johnson
Merck
Pfizer
Schering-Plough
Syntex
Upjohn
Warner Lambert
13
- 40 -
<PAGE>
<PAGE> 41
III. Award Calculation Methodology:
Awards will equal 5% of Base Salary (to a maximum of 50%) for each 1% of growth
in Net Income in excess of the average growth rate of the comparable companies.
A 5% of Base Salary reduction will be made to the Account of each Senior
Partner for each 1% of growth of Net Income below the average growth rate of
the comparable companies. The following examples depict how Awards or
reductions are determined - in example 1, RPR's growth in net income exceeds
that of the comparable companies and there is a resulting Award. In example 2,
RPR's performance lags those companies and there is a reduction to each
Senior Partner's Account.
Example 1 - Assumptions:
- Performance Period 1994 - 1996;
- Industry Net Income growth averages 5%;
- RPR Net Income growth is 8%;
- Exceeding the comparable companies by 3% equals a 15% of Base Salary
Award (each 1% in excess of the comparable companies' average equals
a 5% of Base Salary contribution, up to a maximum of 50%); and
- RPR estimated share price when performance is measured, $70.
<TABLE>
<C> <C> <C> <C> <C> <C>
Base Salary in RPR 3-Year 3-Year $ Value of RPR Share Actual
last year of Performance Award % Annual Price Phantom
Performance v. Industry Contribution Share Award
Period +/(-)
- -------------------------------------------------------------------------------
$200,000 +3% +15% of Base $30,000 $70.00 429
Salary
</TABLE>
14
- 41 -
<PAGE>
<PAGE> 42
Example 2 - Assumptions
- Performance Period 1994 - 1996;
- Industry Net Income growth averages 6%;
- RPR Net Income growth is 5%;
- Lagging the comparable companies by 1% triggers a 5% reduction to the
Senior Partner's Account; and
- RPR estimated share price when performance is measured, $70.
<TABLE>
<C> <C> <C> <C> <C> <C>
Base Salary in RPR 3-Year 3-Year $ Amount RPR Share Actual
last year of Performance Award % Plan Price Phantom
Performance v. Industry Reduction Share
Period +/(-) Reduction
- -------------------------------------------------------------------------------
$200,000 -1% -5% of ($10,000) $70.00 (143)
Salary
</TABLE>
15
- 42 -
<PAGE>
<PAGE> 43
EXHIBIT 10c.
RHONE-POULENC RORER INC.
EXECUTIVE DEFERRAL PLAN
-----------------------
In recognition of the services provided by certain key employees, the Board of
Directors of Rhone-Poulenc Rorer Inc. wishes to make additional retirement
benefits available to those individuals under the terms and conditions
hereinafter set forth.
ARTICLE 1
Definitions
--------------
1.1"Account" means a bookkeeping account established pursuant to Section 3.1
which reflects the amount standing to the credit of the Participant under
the Plan.
1.2"Affiliated Company" means any affiliate or subsidiary of the Company.
1.3"Base Salary" means the annual amount of base salary and wages paid by the
Employer to an Employee for any calendar year of employment, but excluding
all Employer contributions to benefit plans and all other forms of
compensation.
1.4"Beneficiary" means the person(s) designated by a Participant to receive
any benefits payable under this Plan subsequent to the Participant's
death. In the event a Participant has not filed a Beneficiary designation
with the Company, the Beneficiary shall be the Participant's estate.
1.5"Board" means the Board of Directors of the Company.
1.6"Bonus" shall mean bonus compensation due to the Employee, if any, under the
Company's Annual Performance Incentive Plan.
1.7"Code" means the Internal Revenue Code of 1986, as amended.
1.8"Committee" means the Executive Personnel and Compensation Committee of the
Board which shall act for the Company in making decisions and performing
specified duties with respect to the Plan.
1.9"Company" means Rhone-Poulenc Rorer Inc. and its successors.
1.10"Effective Date" means December 1, 1993.
1
- 43 -
<PAGE>
<PAGE> 44
1.11"Employee" means any individual employed by the Employer in employment
grade 36 or higher on a regular, full-time basis (in accordance with
the personnel policies and practices of the Employer), including citizens
of the United States employed outside of and resident aliens employed in
the United States.
1.12"Employer" means the Company and/or any Participating Employer, either
collectively or individually, as the context requires.
1.13"Participant" means any Employee who satisfies the eligibility
requirements set forth in Article 2. In the event of the death or
incompetency of a Participant, the term shall mean his personal
representative or guardian. An individual shall remain a Participant
until that individual has received full distribution of any amount credited
to the Participant's Account.
1.14"Participating Employer" means any Affiliated Company which is designated
by the Board as a Participating Employer under the Plan and whose
designation as such has become effective upon acceptance of such status
by the board of directors of the Affiliated Company. A Participating
Employer may revoke its acceptance of such designation at any time, but
until such acceptance has been revoked, all the provisions of the Plan
and amendments thereto shall apply to the Employees of the Participating
Employer. In the event the designation as a Participating Employer
is revoked by the board of directors of an Affiliated Company, the
Plan shall be deemed terminated only with respect to such Participating
Employer. A list of the Participating Employers in the Plan is
attached hereto as Exhibit A.
1.15"Plan" means the Rhone-Poulenc Rorer Inc. Executive Deferral Plan as the
same is set forth herein, and as it may be amended from time to time.
1.16"Plan Administrator" means the Company's Pension Committee when acting as
the administrator of the Plan.
1.17"Plan Year" means the calendar year.
1.18"Savings Plan" means the Rhone-Poulenc Rorer Inc. Employee Savings Plan,
as it may be amended from time to time.
1.19"Separates from Employment" means the Employee's termination of employment
from the Employer for any reason. Except as otherwise provided herein,
a Separation from Employment shall be deemed to have occurred on the
last day of the Employee's service to the Employer and shall be determined
without reference to any compensation continuation arrangement or
severance benefit arrangement that may be applicable.
2
- 44 -
<PAGE>
<PAGE> 45
ARTICLE 2
Eligibility
-------------
2.1 Each Employee shall be eligible to participate in the Plan on such date
as is specified by the Committee . A list of the individuals
participating in the Plan on the Effective Date is attached hereto
as Exhibit B; such list may be modified from time to
time by the Committee.
ARTICLE 3
Benefits
-----------
3.1 The Plan Administrator shall cause the Employer to create and maintain
on its books an Account for each Participant to which it shall
credit amounts contributed to the Plan pursuant to this Article 3.
The Employer shall also credit each Participant's Account with deemed
earnings for each Plan Year in accordance with the provisions of
Article VIII hereof.
3.2 No later than 6 months after the commencement of any Plan Year, a
Participant may elect to have the Employer credit to the
Participant's Account (as a result of payroll reduction) an
amount equal to any whole percentage or dollar amount of the Participant's
Bonus, if any, to be earned for that Plan Year. With the permission of the
Committee, for any Plan Year, a Participant may also elect to have the
Employer contribute to the Participant's Account (as a result of payroll
reduction) an amount equal to any whole percentage or dollar amount of the
Participant's Base Salary to be earned during the balance of that Plan Year.
If an election is made to have a contribution credited to the Participant's
Account for a Plan Year, the credit shall be made at the time that such
amount would otherwise have been paid and shall reduce
the Participant's Bonus (or Base Salary, if applicable) with respect to
that Plan Year by a corresponding amount. The Committee may establish
minimum or maximum amounts that may be deferred under this Section and
may change such standards from time to time. Any such limits shall be
communicated by the Committee to the Plan Administrator and by the
Plan Administrator to the Participants prior to the commencement of a
Plan Year.
3.3 Any elections under this Article shall be made in writing on such form as
the Plan Administrator shall specify. Unless otherwise permitted
by the Committee, in its sole discretion, any such election with respect to
a Plan Year must be made no later than June 30 of that Plan Year in which
the Bonus would be earned by the Participant. Any election by a
Participant pursuant to this Section 3.3 shall be irrevocable and may not
be modified in any respect.
3
- 46 -
<PAGE>
<PAGE> 47
ARTICLE 4
Distributions to Participants
-----------------------------
4.1 A Participant's benefit payment under the Plan shall be in one lump
sum and shall be paid as
soon as practicable following the completion of the valuation of the
Participant's Account for
the last day of the month in which the Participant Separates from
Employment; provided,
however, that in the event that the Participant Separates from Employment
on or after
attaining (a) age 65, or (b) age 55 with at least 5 years of employment,
the Participant may
elect, in the manner and at the time provided by the Plan Administrator,
to receive such
distribution in (a) one lump sum on the earlier of (i) the first business
day of the second
calendar quarter following the date the Participant Separates from
Employment or (ii) the first
day of the Plan Year following the date the Participant Separates from
Employment or (b)
monthly installments over a period not to exceed 15 years commencing on
the first day of the
Plan Year following the date on which the Participant Separates
from Employment (with the
balance to be distributed continuing to be credited with deemed
earnings for each subsequent
Plan Year in accordance with the provisions of Article 8 hereof); and
provided, further, that
in the event that such a Participant fails to make an election,
distribution shall be in the form specified in clause (b).
4.2 If the event that a Participant incurs a "significant financial hardship"
while employed by the
Employer, as determined by the Plan Administrator, the Participant may
apply, in writing, for
a withdrawal of all or a portion of the balance credited to the
Participant's Account in the
form of a lump sum. All determinations by the Plan Administrator regarding
the existence of
a financial hardship shall be made in accordance with the provisions of the
Company's
Savings Plan dealing with whether a financial hardship exists for
purposes of permitting
withdrawals thereunder. The Plan Administrator shall determine whether to
permit a such a
withdrawal and, based upon the Participant's application, the amount
necessary to satisfy that
hardship, which shall be distributed in a single sum as soon as practicable
after the Plan
Administrator's determination.
4.3 In the event that a Participant wishes to withdraw amounts credited to the
Participant's Account in the form of a lump sum prior to Separation from
Employment but without
incurring a "significant financial hardship," as required by Section
4.2 hereof, the Participant
4
- 46 -
<PAGE>
<PAGE> 47
may elect to receive all or a portion of the balance credited to the
Participants's Account that
is attributable to a particular deferral election for a Plan Year by filing
a written election with
the Plan Administrator at the time that such amount is deferred under the
Plan, pursuant to
Section 3.2 hereof, specifying a percentage of the amount so deferred
(including earnings) to
be distributed and the date that such distribution is to be made which
must be at least 2 years
following the Plan Year in which the deferral is credited to the
Participant's Account under Section 3.2 hereof.
ARTICLE 5
Death Benefit
-------------
5.1 In the event of the death of a Participant prior to the payment of a
benefit pursuant to Article
4, the Participant's Beneficiary shall receive a lump sum
distribution equal to the balance of
the Participant's Account on the date of death. The benefit payment to
the Beneficiary will
be made as soon as practicable following the completion of the
valuation of the deceased
Participant's Account. In the event of the death of a Participant after
payment of a benefit
has commenced in installments, pursuant to Section 4.1 hereof,
the Participant's Beneficiary
shall continue to receive the payments due following the
Participant's death.
ARTICLE 6
Vesting
-------
6.1 The balance credited to a Participant's Account shall be fully vested
at all times.
ARTICLE 7
Funding
---------
7.1 The Board may, but shall not be required to, authorize the establishment
of a trust by the
Employer to serve as the funding vehicle for the benefits described
in Article 3 hereof. In any event, the Employer's obligation hereunder
shall constitute a general, unsecured
obligation, payable solely out of its general assets, and no Participant
shall have any right to
any specific assets of the Employer. In addition, it is the intention
of the Employer that the
Plan be unfunded for tax purposes and for purposes of Title I of the
Employee Retirement
Income Security Act of 1974, as amended.
5
- 47 -
<PAGE>
<PAGE> 48
ARTICLE 8
Investments
-----------
8.1 The balance of a Participant's Account shall be deemed to be invested in an
interest bearing
instrument which shall provide for interest to be credited and
compounded daily at an
effective rate equal to the Merrill Lynch Bond Index of 1 - 10 year
corporate high quality
bond yields, or such other index specified by the Committee if the Merrill
Lynch Index is no
longer published, such rate to be adjusted quarterly based on the rate as
of the last business day of each calendar quarter. Interest shall be
applied to the average balance of each
Participant's Account during the prior quarter.
ARTICLE 9
Administration
--------------
9.1 The Plan Administrator shall have full power and authority to interpret the
Plan, to prescribe,
amend and rescind any rules, forms and procedures as it deems necessary
or appropriate for
the proper administration of the Plan and to make any other
determinations and to take any
other such actions as it deems necessary or advisable in carrying out its
duties under the Plan.
All action taken by the Plan Administrator arising out of, or in connection
with, the
administration of the Plan or any rules adopted thereunder, shall,
in each case, lie within its
sole discretion, and shall be final, conclusive and binding upon
the Employer, the Board, all
Employees, all beneficiaries of Employees and all persons and
entities having an interest
therein.
9.2 Members of the Committee and the Plan Administrator shall serve without
compensation for
their services unless otherwise determined by the Board. All expenses of
administering the
Plan shall be paid by the Employer.
9.3 The Company shall indemnify and hold harmless each member of the Committee
and the Plan
Administrator from any and all claims, losses, damages, expenses (including
counsel fees)
and liability (including any amounts paid in settlement of any claim or
any other matter with
the consent of the Board) arising from any act or omission of such member,
except when the
same is due to gross negligence or willful misconduct.
9.3[sic] Any decisions, actions or interpretations to be made under the Plan
by the Company,
Employer or Committee shall be made in its sole discretion and need not be
uniformly applied
6
- 48 -
<PAGE>
<PAGE> 49
to similarly situated individuals and shall be final, bining and
conclusive on all persons interested in the Plan.
ARTICLE 10
Amendment
----------
10.1 The Plan may be amended by the Committee at any time and from time to
time all without
prior notice to any person or entity; provided, however, that no such
amendment shall have
the effect of divesting a Participant of the benefit which the
Participant would otherwise receive hereunder at the time the
amendment is adopted.
ARTICLE 11
Termination
-----------
11.1 Continuance of the Plan is completely voluntary and is not assumed
as a contractual
obligation of the Employer. The Committee, acting on behalf of the
Employer, shall have the
right to terminate the Plan in whole or in part at any time all
without prior notice to any
person or entity; provided, however, that such termination shall not
have the effect of
divesting a Participant of the benefit which the Participant would
otherwise receive hereunder
at the time of the termination.
ARTICLE 12
Miscellaneous
--------------
12.1 Nothing contained herein (a) shall be deemed to exclude a Participant
from any compensation,
bonus, pension, insurance, severance pay or other benefit to which
he otherwise is or might
become entitled as an Employee or (b) shall be construed as
conferring upon an Employee the
right to continue in the employ of the Employer.
12.2 Any amounts payable hereunder shall not be deemed salary or other
compensation to a
Participant for the purposes of computing benefits to which the
Participant may be entitled
under any other arrangement established by the Employer for the
benefit of its employees.
12.3 The rights and obligations created hereunder shall be binding on
a Participant's heirs,
executors and administrators and on the successors and assigns of the
Employer.
7
- 49 -
<PAGE>
<PAGE> 50
12.4 The masculine pronoun whenever used shall include the feminine and the
singular shall be construed as the plural, where applicable.
12.5 The provisions of the Plan shall be construed and applied under the
laws of the Commonwealth of Pennsylvania.
12.6 The rights of any Participant under this Plan are personal and may
not be assigned,
transferred, pledged or encumbered. Any attempt to do so shall
be void. In addition, a
Participant's rights hereunder are not subject, in any manner,
to anticipation, alienation, sale,
transfer, assignment, pledge, encumbrance, attachment or garnishment
by creditors of the
Participant or the Participant's Beneficiary.
12.7 If any provision of the Plan shall be held invalid or unenforceable,
such invalidity or
unenforceability shall not effect any other provisions hereof and
the Plan shall be construed
and enforced as if such provisions had not been included.
12.8 The headings and captions herein are provided for convenience only,
and shall not be
construed as part of the Plan, and shall not be employed in the
construction of the Plan.
12.9 Any benefit payable to or for the benefit of a payee who is a
minor, an incompetent person,
or is otherwise incapable of receipting therefore shall be deemed
paid when paid to such
person's guardian or to the party providing, or a reasonably
appearing to provide, the care for
such person, and such payment shall fully discharge the Employer,
the Committee, the Plan
Administrator, the Board and all other parties with respect thereto.
8
- 50 -
<PAGE>
<PAGE> 51
EXHIBIT A
PARTICIPATING EMPLOYERS
Armour Pharmaceutical Company
Dermik Laboratories
Plasma Alliance Inc.
Rhone-Poulenc Rorer Inc.
Rhone-Poulenc Rorer Pharmaceuticals Inc.
- 51 -
<PAGE>
<PAGE> 52
EXHIBIT B
1994 BASE SALARY DEFERRAL ELECTIONS
PARTICIPATING EMPLOYEES AND EMPLOYERS AS OF FEBRUARY 1, 1994
NOT FILED
- 52 -
<PAGE>
<PAGE> 53
EXHIBIT 11
RHONE-POULENC RORER INC. AND SUBSIDIARIES
Computation of Earnings Per Common Share
(Unaudited-dollars and shares in millions except per share data)
<TABLE>
<CAPTION>
Three Months Three Months
Ended Ended
March 31, December 31,
--------------- --------------
1994 1993
--------------- --------------
Per Per
Dollars Share Dollars Share
<S> <C> <C> <C> <C>
Net income per common share as
reported:
Net income before preferred
dividend $ 77.9 $ 96.4
Less: Dividend on preferred stock (4.2) (2.2)
--------- ---------
Net income available to common
shareholders $ 73.7 $ .54 $ 94.2 $.68
========= ====== ======== ======
Average shares outstanding 136.5 138.3
========= ========
Net income per common share
assuming full dilution:
Net income before preferred
dividend $ 77.9 $ 96.4
Less: Dividend on preferred stock (4.2) (2.2)
--------- --------
Net income available to common
shareholders $ 73.7 $ .54 $ 94.2 $.68
========= ====== ======== =====
Average shares outstanding 136.5 138.3
Shares contingently issuable
for stock plan .4 .9
--------- --------
Average shares outstanding,
assuming full dilution 136.9 139.2
========= ========
<FN>
This calculation is submitted in accordance with the regulations of the
Securities and Exchange Commission although not required by APB Opinion
No. 15 because it results in dilution of less than 3%.
</FN>
</TABLE>
- 53 -
<PAGE>
<PAGE> 54
EXHIBIT 15
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, DC 20549
RE: Rhone-Poulenc Rorer Inc.
Quarterly Report on Form 10-Q
We are aware that our report dated April 22, 1994, on our review of
interim financial information of Rhone-Poulenc Rorer Inc. (the Company),
for the period ended March 31, 1994, and included in the Company's
quarterly report on Form 10-Q for the quarter then ended is incorporated
by reference in the registration statements of the Company on Form S-3
(Registration No. 33-62052, Registration No. 33-36558, Registration No.
33-30795, Registration No. 33-23754, Registration No. 33-4876,
Registration No. 33-19936, Registration No. 22-18034, Registration No.
33-43941, Registration No. 33-53378 and Registration No. 33-55694) and
on Form S-8 (Registration No. 33-58998, Registratin No. 33-24537,
Registration No. 2-61635, Registration No. 2-78374 and Registration No.
33-2403). Pursuant to Rule 436(c) under the Securities Act of 1933,
this report should not be considered a part of the registration
statements prepared or certified by us within the meaning of Sections 7
and 11 of that Act.
/S/COOPERS & LYBRAND
----------------------------------------
COOPERS & LYBRAND
Philadelphia, Pennsylvania
May 13, 1994
- 54 -
